Development of matrix metalloproteinase inhibitors in cancer therapy

Hematology/Oncology Clinics of North America

Volumn 16, Issue 5, 2002, Pages 1189-1227

  Purcell, W Thomas ^a   Rudek, Michelle A ^a   Hidalgo, Manuel ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; ANTINEOPLASTIC AGENT; BATIMASTAT; BB 2511; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; CGS 27023A; CLODRONIC ACID; CORTICOSTEROID; CYTOTOXIC AGENT; DOXYCYCLINE; FLUOROURACIL; GEMCITABINE; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MMI 270B; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PRINOMASTAT; REBIMASTAT; TANOMASTAT; TEMOZOLOMIDE; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG; PROTEINASE INHIBITOR; TUMOR PROTEIN;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BLEEDING; CANCER; CANCER COMBINATION CHEMOTHERAPY; CATARACT; CLINICAL RESEARCH; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DYSPNEA; ENZYME ACTIVITY; ENZYME REGULATION; FATIGUE; FEVER; FIBROSIS; GASTROINTESTINAL TOXICITY; HUMAN; INFLAMMATION; LIVER TOXICITY; MOTOR DYSFUNCTION; MUSCLE STIFFNESS; MYALGIA; NAUSEA; NONHUMAN; PAIN; PHOTOTOXICITY; POLYARTHRITIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PRURITUS; REVIEW; TENDINITIS; TENOSYNOVITIS; TISSUE NECROSIS; VOMITING; WEIGHT REDUCTION; CANCER INVASION; DRUG ANTAGONISM; DRUG DESIGN; DRUG SCREENING; ENZYMOLOGY; FORECASTING; NEOPLASM; PHYSIOLOGY; VASCULARIZATION;

CLINICAL TRIALS; DIPHOSPHONATES; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FORECASTING; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASMS; PROTEASE INHIBITORS; TETRACYCLINES;

EID: 0036817030     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(02)00044-8     Document Type: Review

References (196)

1. Chambers AF, Matrisian L. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-70.
2. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 1999;31:34-45.
3. Ray JM, Stetler-Stevenson WG. Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J 1995;14:908-17.
4. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999;43(Suppl):S42-51.
5. Denis LJ, Verweij J. Matrix metalloproteinase inhibitors: Present achievements and future prospects. Invest New Drugs 1997;15:175-85.
6. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997;15:61-75.
7. Brown PD. Clinical studies with matrix metalloproteinase inhibitors. APMIS 1999;107: 174-80.
8. Fini ME, Cook JR, Mohan R, Brinckerhoff CE. Regulation of matrix metalloproteinase gene expression. In: Parks W, Mechan R, editors. Matrix Metalloproteinases. San Diego: Academic Press, 1998. p. 300-56.
9. Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: Biological consequences. Curr Opin Cell Biol 1998;10:602-8.
10. Kurogi T, Nabeshima K, Kataoka H, Okada Y, Koono M. Stimulation of gelatinase B and tissue inhibitors of metalloproteinase (TIMP) production in co-culture of human osteosarcoma cells and human fibroblasts: Gelatinase B production was stimulated via up-regulation of fibroblast growth factor (FGF) receptor. Int J Cancer 1996;66:82-90.
11. Kondapaka SB, Fridman R, Reddy KB. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer 1997;70: 722-6.
12. Nuovo GJ. In situ detection of PCR-amplified metalloproteinase cDNAs, their inhibitors and human papillomavirus transcripts in cervical carcinoma cell lines. Int J Cancer 1997;71: 1056-60.
13. Panck RL, Lu GH, Klutchko SR, Batley BL, Dahring TK, Hamby JM, et al. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J Pharmacol Exp Ther 1997;283:1433-44.
14. Mira E, Manes S, Lacalle RA, Marquez G, Martinez A. Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9. Endocrinology 1999; 140:1657-64.
15. Rosenthal EL, Johnson TM, Allen ED, Apel IJ, Punturieri A, Weiss SJ. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells. Cancer Res 1998;58:5221-30.
16. Ellerbroek SM, Hudson LG, Stack MS. Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion. Int J Cancer 1998;78:331-7.
17. Sundareshan P, Nagle RB, Bowden GT. EGF induces the expression of matrilysin in the human prostate adenocarcinoma cell line, LNCaP. Prostate 1999;40:159-66.
18. Duivenvoorden WC, Hirte HW, Singh G. Transforming growth factor beta 1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin Exp Metastasis 1999;17:27-34.
19. Janowska-Wieczorek A, Marquez LA, Nabholtz JM, Cabuhat ML, Montano J, Chang H, et al. Growth factors and cytokines upregulate gclatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane. Blood 1999;93:3379-90.
20. Aoudjit F, Potworowski EF, St-Pierre Y. Bi-directional induction of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 during T lymphoma/endothelial cell contact: Implication of ICAM-1. J Immunol 1998;160:2967-73.
21. Reddy KB, Krueger JS, Kondapaka SB, Diglio CA. Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells. Int J Cancer 1999;82:268-73.
22. Sato H, Okada Y, Seiki M. Membrane-type matrix metalloproteinases (MT-MMPs) in cell invasion. Thromb Haemost 1997;78:497-500.
23. Murphy G, Stanton H, Cowell S, Butler G, Kanauper V, Atkinson S, et al. Mechanism for pro matrix metalloproteinase activation. APMIS 1999;107:38-44.
24. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur J Cell Biol 1997;74:111-22.
25. Henriet P, Blavier L, DeClerck YA. Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation. APMIS 1999;107:111-9.
26. Bode W, Fernandez-Catalan C, Nagase H, Maskos K. Endoproteinase-protein inhibitor interactions. APMIS 1999;107:3-10.
27. Will H, Atkinson S, Butler G, Smith B, Murphy G. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolitic activation. J Biol Chem 1996;271:17119-23.
28. Steams ME, Fudge K, Garcia F, Wang M. IL-10 inhibition of human prostate PC-3 ML cell metastases in SCID mice: IL-10 stimulation of TIMP-1 and inhibition of MMP-2/MMP-9 expression. Invasion Metastasis 1997;17:62-74.
29. Su S, DiBattista JA, Sun Y, Li WQ, Zafarullah M. Up-regulation of tissue inhibitor of metal-loproteinases-3 gene expression by TGF-beta in articular chondrocytes is mediated by serine/ threonine and tyrosine kinases. J Cell Biochcm 1998;70:517-27.
30. Steams ME, Rhim J, Wang M. Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res 1999;5:189-96.
31. Nemeth J, Rafe A, Steiner M, Goolsby C. TIMP-2 growth-stimulatory activity: A concentration and cell type specific response in the presence of insulin. Exp Cell Res 1996;224:110-5.
32. Martin D, Ruther U, Sanchez-Sweatman O, Orr W, Khokha R. Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice. Oncogene 1996;13:569-76.
33. Anand-Apte B, Pepper M, Voest E, Montesano R, Olsen B, Murphy G. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest Opthamol Vis Sci 1997;38:817-23.
34. Yoshiji H, Harris S, Raso E, Gomey D, Lindsay C, Shibuya M. Mammary carcinoma cells overexpressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J Cancer 1998;247:81-7.
35. Seiki M. Membrane-type matrix metalloproteinase. APMIS 1999;107:137-43.
36. Lochter A, Bissell M. An odyssey from breast to bone: Multiple-step control of mammary metastases and osteolysis by matrix metalloproteinases. APMIS 1999;107:128-36.
37. Folkman J. Seminars in medicine of the Best Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-63.
38. Bernhard EJ, Gruber SB, Muschel RJ. Direct evidence linking expression of matrix metal-loproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci U S A 1994;91:4293-7.
39. Hua J, Muschel RJ. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res 1996;56:5279-84.
40. Kawamata H, Kameyama S, Kawai K, Tanaka Y, Nan L, Barch D. Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase A. Int J Cancer 1995;63:568-75.
41. Tsunezuka Y, Kinoh H, Takino T, Watanabe Y, Okada Y, Shinagawa A. Expression of membrane-type matrix metalloproteinase 1 (MTI-MMP) in tumor cells enhances pulmonary metastases in an experimental metastasis assay. Cancer Res 1996;63:5678-83.
42. Powel W, Knox J, Navre M, Grogan T, Kittelson J, Nagle RB. Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in several combined immunodeficient mice. Cancer Res 1993;53:417-22.
43. Wilson CL, Heppner KJ, Labosky PA, Hogan BL, Matrisian LM. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci U S A 1997; 94:1402-7.
44. Itoh H, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998;58:1048-51.
45. Masson R, Lefebvre O, Noel A, Fahime M, Chenard MP, Wendling C. In vivo evidence that the stromeysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol 1998;140:1535-41.
46. Martin DC, Fowlkes JL, Babic B, Khokha R. Insulin-like growth factor II signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1. J Cell Biol 1999;146:881-92.
47. Manes S, Mira E, Barbacid M, Cipres A, Fernandez-Resa P, Buesa J, et al. Identification of insulin like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem 1997;272:25706-12.
48. Davidson B, Goldberg I, Liokumovich P, Kopolovic J, Gotlieb WH, Leer-Geva L, et al. Expression of metalloproteinases and their inhibitors in adenocarcinoma of the uterine cervix. Int J Gynecol Pathol 1998;17:295-301.
49. Kugler A, Hemmerlein B, Thelen P, Kallerhoff M, Radzun HJ, Ringert RH. Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol 1998;160:1914-8.
50. Hashimoto K, Kihira Y, Matuo Y, Usui T. Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate. J Urol 1998;160:1872-6.
51. Sutinen M, Kainulainen T, Hurskainen T, Vesterlund E, Alexander JP, Overall CM, et al. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis. Br J Cancer 1998;77:2239-45.
52. Gonzalez-Avila G, Iturria C, Vadillo F, Teran L, Selman M, Perez-Tamayo R. 72-kD (MMP-2) and 92-kD (MMP-9) type IV collagenase production and activity in different histologic types of lung cancer cells. Pathobiology 1998;66:5-16.
53. Nawrocki B, Polette M, Marchand V, Monteau M, Gillery P, Toumier JM, et al. Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: Quantificative and morphological analyses. Int J Cancer 1997;72:556-64.
54. Bramhall SR. The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application. Int J Pancreatol 1997;21:1-12.
55. Zucker S, Hymowitz M, Conner C, Zarrabi HM, Hurewitz AN, Matrisian L, et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci 1999;878:212-27.
56. Dano K, Romer J, Nielsen B, Bjom S, Pyke C, Rygaard J, et al. Cancer invasion and tissue remodeling-cooperation of protease systems and cell types. APMIS 1999;107:120-7.
57. Johansonn N, Airola K, Grenman R, Kariniemi AL, Saarialho-Kere U, Kahari VM. Expression of most matrixmetalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 1997;151:273-89.
58. Uria A, Stahle-Backdahl M, Seiki M, Fueyo A, Lopez-Otin C. Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal epithelial cell interactions. Cancer Res 1997;57:4882-8.
59. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinases family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996;149:273-82.
60. Airola K, Karonen T, Vaalamo M, Lehti K, Lohi J, Kariniemi AL, et al. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer 1999;80:733-43.
61. Ozdemir E, Kakehi Y, Okuno H, Yoshida O. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas. J Urol 1999;161:1359-63.
62. MacDougall JR, Bani MR, Lin Y, Muschel RJ, Kerbel RS. "Proteolytic switching": Opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression. Br J Cancer 1999;80:504-12.
63. Iwata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N, Okada Y. Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res 1996;87:602-11.
64. Rha SY, Yang WI, Kim JH, Roh JK, Min JS, Lee KS, et al. Different expression patterns of MMP-2 and MMP-9 in breast cancer. Oncol Rep 1998;5:875-9.
65. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in esophageal cancer. J Pathol 1998;185:256-61.
66. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996;2:461-2.
67. Yamamoto H, Adachi Y, Itoh F, Iku S, Matsuno K, Kusano M, et al. Association of matrylisin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer Res 1999;59:3313-6.
68. Fingleton BM, Heppner GK, Crawford HC, Matrisian LM. Matrilysin in early stage intestinal tumorigenesis. APMIS 1999;107:102-10.
69. Shoji A, Sakamoto Y, Tsuchiya T, Moriyama K, Kaneko T, Okubo T, et al. Inhibition of tumor promoter activity toward mouse fibroblasts and their in vitro transformation by tissue inhibitor of metalloproteinases-1 (TIMP-1). Carcinogenesis 1997;18:2093-100.
70. Kruger A, Sanchez-Sweatman OH, Martin DC, Fata JE, Ho AT, Orr FW, et al. Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line. Oncogene 1998;16:2419-23.
71. Koop S, Khokha R, Schmidt EE, MacDonald IC, Morris VL, Chambers AF. Overexpression of metalloproteinase inhibitor in B161710 melanoma cells does not affect extravasation but reduces tumor growth. Cancer Res 1994;54:4791-7.
72. Bramhall SR, Neoptolemos JP, Stamp GW, Lemoine NR. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 1997;182:347-55.
73. Zeng Z, Cohen A, Zhang Z, Stetler-Stevenson W, Guillem J. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with kymph nodes and distinct metastasis. Clin Cancer Res 1995;1:899-906.
74. Fong K, Kida Y, Zimmermann P, Smith P. TIMP-1 and adverse prognosis in non-small cell lung cancer. Clin Cancer Res 1996;2:1364-72.
75. Powe D, Brough J, Carter G, Ravery V, Angulo J, Shamsa F. TIMP-3 mRNA expression is regionally increased in moderately and poorly differentiated colorectal adenocarcinoma. Br J Cancer 1997;75:1678-83.
76. Newell K, Witty J, Rodgers W, Matrisian L. Expression and localization of matrix degrading metalloproteinases during colorectal tumorigenesis. Mol Carcinog 1994;10: 199-206.
77. Yoshiji H, Gomez D, Horgeirsson U. Enhanced RNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in human breast cancer. Br J Cancer 1996;69:131-4.
78. Karameris A, Panagou P, Tsilalis T, Bouros D. Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous lung carcinomas. Am J Respir Crit Care Med 1997;156:1930-6.
79. McCarthy K, Maguire T, McGreal G, McDermott E, O'Higgins N, Duffy MJ. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 1999;84:44-8.
80. Simon C, Goepfert H, Boyd D. Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion. Cancer Res 1998;58:1135-9.
81. Simon C, Juarez J, Nicolson GL, Boyd D. Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase, on urokinase expression and in vitro invasion. Cancer Res 1996;56: 5369-74.
82. Hasegawa S, Koshikawa N, Momiyama N, Moriyama K, Ichikawa Y, Ichikawa I. Matrylysin-specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model. Int J Cancer 1998;76:812-6.
83. Ahonen M, Baker AH, Kahari VM. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinase-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res 1998;58:2310-5.
84. Bian J, Wang Y, Smith M, Kim H, Jacobs C, Jackman J. Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinase-3 (TIMP-3). Carcinogenesis 1996;17:1805-11.
85. Brown PD. Matrix metalloproteinase inhibitors. Breast Cancer Res Treat 1998;52:125-36.
86. Betz M, Huxley P, Davies SJ, Mushtaq Y, Pieper M, Tschesche H, et al. 1.8-A crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile. Eur J Biochem 1997;247:356-63.
87. Wang X, Fu X, Brown P, Crimmin M, Hoffman RM. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spreads in a patient-like orthotopic model in nude mice. Cancer Res 1994;54:4726-8.
88. Bu W, Tang ZY, Sun FX, Ye SL, Liu KD, Xue Q, et al. Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20. Hepatogastroenterology 1998;45:1056-61.
89. Taraboletti G, Garofalo A, Belotti D, Drudis T, Borsotti P, Scanziani E, et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrixmetalloproteinases. J Natl Cancer Inst 1995;87:293-8.
90. Zervos EE, Norman JG, Gower WR, Franz MG, Rosemurgy AS. Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo. J Surg Res 1997;69:367-71.
91. Chirivi R, Garofalo A, Crimmin M, Bawden L, Stoppacciaro A, Brown P, et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinases. Int J Cancer 1994;58:460-4.
92. Watson SA, Morris T, Robinson G, Crimmin M, Brown PD, Hardcastle J. Inhibition of organ invasion by matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 1995;55:3629-33.
93. Eccles SA, Box GM, Court WJ, Bone EA, Thomas W, Brown PD. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 1996;56:2815-22.
94. Wylie S, MacDonald IC, Varghese HJ, Schmidt EE, Morris VL, Groom AC, et al. The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells. Clin Exp Metastasis 1999;17:111-7.
95. Davies BD, Brown P, East N, Crimmin M, Balkwill FR. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian cancer xenografts. Cancer Res 1993;53:2087-91.
96. Low JA, Johnson MD, Bone EA, Dickson RB. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin Cancer Res 1996;2:1207-14.
97. Giavazzi R, Garofalo A, Ferri C, Lucchini V, Bone EA, Chiari S, et al. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian cancer. Clin Cancer Res 1998;4:985-92.
98. Prontera C, Mariani B, Rossi C, Poggi A, Rotilio D. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer 1999;81:761-6.
99. Wojtowicz-Praga S, Low J, Marshall J, Ness E, Dickson R, Barter J, et al. Phase 1 trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest New Drugs 1996;14:193-202.
100. Macaulay VM, O'Byrne KJ, Saunders MP, Braybrooke JP, Long L, Gleeson F, et al. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 1999;5:513-20.
101. Beattie G, Smyth J. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascitis. Clin Cancer Res 1998;4:1899-902.
102. Wojtowicz-Praga S, Torri J, Johnson M, Steen V, Marshall J, Ness E, et al. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 1998;16:2150-6.
103. Millar A, Brown P, Moore J, Galloway WA, Cornish A, Lenehan T, et al. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br J Clin Pharmacol 1998;45:21-6.
104. Primrose J, Bleiberg H, Daniel F, Van Belle S, Mansi J, Seymour M, et al. Marimastat in recurrent colorectal cancer: Exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. Br J Cancer 1999;79:509-14.
105. Rosemurgy A, Harris J, Langleben A, Casper E, Goodc S, Rasmussen H. Marimastat in patients with advanced pancreatic cancer: A dose-finding study. Am J Clin Oncol 1999;22:247-52.
106. Bourthe A, Eisenhauer E, Steward W, Rusthoven I, Quirt R, Lohmann R, et al. Phase I-II study of marimastat (BB2516) in patients (pts) with metastatic melanomas [abstract]. Proc Am Soc Clin Oncol 1997;16:493.
107. Carmichael J, Lederman J, Woll PGT, Russell R. Phase IB study of concurrent administration of marimatat and gemcitabine in non-resectable pancreatic cancer [abstract]. Proc Am Soc Clin Oncol 1998;17:232.
108. O'Reilly S, Mani S, Ratain M, Elza K, Brown S, Jonhson S, et al. Schedules of 5-FU and the matrix metalloproteinase inhibitor marimastat (MAR): A phase 1 study [abstract]. Proc Am Soc Clin Oncol 1998;17:217.
109. Adams M, Thomas H. A phase I study of the matrix metalloproteinase inhibitor, marimastat, administered concurrently with carboplatin, to patients with relapse ovarian cancer [abstract]. Proc Am Soc Clin Oncol 1998;17:217.
110. Anderson IC, Supko J, Eder J, Vasconcelles M, Shapiro G, Skarin A, et al. Pilot pharmacokinetic study of marimastat (MAR) in combination with carboplatin (C)/Paclitaxel (T) in patients with metastatic or locally advanced inoperable non-small cell lung cance (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1999;18.
111. Steward WP. Marimastat (BB2516): Current status and development. Cancer Chemother Pharmacol 1999;43:S56-60.
112. Eisenberger M, Sinibaldi V, Laufer M, Carducci M, Miller P, Boasberg F, et al. Phase I/+ pharmacokinetic evaluation of marimastat in patients (pts) with advanced prostate cancer (PC): Identification of the biological active dose [abstract]. Proc Am Soc Clin Oncol 2000;19:336.
113. Miller KD, Gradishar WJ, Schuchter L, Sparano JA, Cobleigh MA, Robert NJ, et al. A randomized phase II pilot trial of adjuvant marimastat (MAR) in patients (pts) with early breast cancer [abstract]. Proc Am Soc Clin Oncol 2000;19:96.
114. Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of a biological active and tolerable dose for long term studies. Clin Cancer Res 1998;4:1101-9.
115. Evans JD, Stark A, Johnson CD, Daniel F, Carmichael J, Buckels J, et al. A phase II trial of marimastat in advanced pancreatic cancer. Br J Cancer 2001;85(12):1865-70.
116. Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Alfred Yung WK, et al. Phase II trial of temozolomide plus the matrix metalloprotcinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 2002;25:1383-8.
117. Nelson AR, Fingleton BM, Rothenberg ML, Matrisian LM. Matrix metalloproteinase: Biologic activity and clinical implications. J Clin Oncol 2000;18:1135-49.
118. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial. J Clin Oncol 2001;19: 3445-7.
119. Fielding J, Scholefield J, Stuart P, Hawkins R, McCulloch P, Maughan T, et al. A randomized double-blind placebo controlled study of marimastat in patients with inoperable gastric adenocarcinoma [abstract]. Proc Am Soc Clin Oncol 2000;929.
120. Hibner B, Card A, Flynn C, Casazza A, Taraboletti G, Rieppi M, et al. Bay 12-9566, a novel biphenyl matrix metalloproteinase inhibitor, demonstrated anti-invasive and anti-angiogenic properties [abstract]. Proc Am Assoc Can Res 1998;39:302.
121. Bull C, Flynn C, Eberwein D, Casazza A, Carter C, Hibner B. Activity of the biphenyl matrix metalloproteinase inhibitor Bay 12-9566 in murine in vivo models [abstract]. Proc Am Assoc Can Res 1998;39:302.
122. Flynn C, Bull C, Eberwein D, Matheme C, Hibner B. Anti-metastatic activity of Bay 12-9566 in a human colon carcinoma HCT116 orthotopic model [abstract]. Proc Am Assoc Can Res 1998;39:301.
123. Nozaki S, Sissons S, Casazza A, Sledge GWJ. Inhibition of human breast cancer regrowth and pulmonary metastasis by Bay 12-9566 in athymie mice [abstract]. Proc Am Assoc Can Res 1998;39.
124. Clemens G, Detzer K, Bomhard E, von Keutz E. Preclinical drug safety profile for the antimetastatic matrix metalloproteinase inhibitor agent Bay 12-9566 [abstract]. Proc Nat Can Inst-Eur Org Res Treat Can 1998.
125. Perrino P, Ward D. [14C] Bay 12-9566: Assessment of enterohepatic cycling in male rats following intraduodenal administration [abstract]. Proc Am Assoc Can Res 1999;40:391.
126. Chien D, Daly D, Brubaker W. Pharmacokinetics of Bay 12-9566 in guinea pigs following intravenous and oral administration [abstract]. Proc Am Assoc Can Res 1998;40:390.
127. Rowinsky E, Humphrey R, Hammond L, Aylesworth C, Smetzer L, Hidalgo M, et al. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J Clin Oncol 2000; 18:178-86.
128. Goel R, Hirte H, Major P, Waterfield B, Holohan S, Bennett K, et al. Clinical pharmacology of the metalloproteinase (MMP) and angiogenesis inhibitor Bayer 12-9566 in cancer patients [abstract]. Proc Am Soc Clin Oncol 1999;18:160a.
129. Erlichman C, Adjei A, Alberts S, Sloan J, Goldberg R, Pitot H, et al. Phase I study of Bay 12-9566-a matrix metalloproteinase inhibitor (MMPI) [abstract]. Proc Am Soc Clin Oncol 1998; 17:217a.
130. Grochow L, O'Reilly S, Humphrey R, Sundareshan P, Donehower R, Sartorious S, et al. Phase I and pharmacokinetic study of the matrix metalloproteinase inhibitor (MMPI) Bay 12-9566 [abstract]. Proc Am Soc Clin Oncol 1998;17:231a.
131. Tolcher A, Rowinsky E, Rizzo J, Britten C, Siu L, Humphrey R, et al. A phase I and pharmacokinetic study of the oral matrix metalloproteinase inhibitor Bay 12-9566 in combination with paclitaxel and carboplatin [abstract]. Proc Am Soc Clin Oncol 1999;18:160.
132. Hirte H, Goel R, Major P, Waterfield B, Holohan S, Bennett K, et al. Pharmacokinetics of Bay 12-9566: Early results of a Canadian phase I dose escalation study in cancer patients [abstract]. Proc Am Assoc Can Res 1998;39:364.
133. Grochow L. Preclinical and clinical pharmacology of matrix metalloproteinase inhibitor (MMPIs) [abstract]. Proc Nat Can Inst-Eur Org Res Treat Cancer 1998.
134. Rowinsky E, Humphrey R, Hammond L, Aylesworth C, Smetzer L, Hidalgo M, et al. A phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor Bay 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J Clin Oncol 2000;18: 178-86.
135. Moore MJ, Hamm P, Eisenberg P, Dagenais M, Hagan K, Fields A, et al. A comparison between gemcitabine (GEM) and the matrix metalloproteinase (MMP) Inhibitor BAY12-9566 (9566) in patients (pts) with advanced pancreatic cancer [abstract]. Proc Am Soc Clin Oncol 2000;19:240a.
136. Shalinsky DR, Brekken J, Zou H, McDermott CD, Forsyth P, Edwards D, et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci 1999;878:236-70.
137. Santos O, McDermott CD, Daniels R, Appelt K. Rodent pharmacokinetics and anti-tumor efficacy studies with a series of synthethic inhibitors of matrix metalloproteinases. Clin Exp Metastasis 1997;15:499-508.
138. Shalinsky DR, Brekken J, Zou H, Kolis S, Wood A, Webber S, et al. Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations. Invest New Drugs 1998;16:303-13.
139. Shalinsky D, Brekken J, Zou H, Bloom L, McDermott CD, Zook S, et al. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: Single agent and combination chemotherapy studies. Clin Cancer Res 1999;5:1905-17.
140. Price A, Shi Q, Morris D, Wilcox ME, Brasher PM, Rewcastle NB, et al. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin Cancer Res 1999;5:845-54.
141. Hande K, Wilding G, Ripple G, Fry J, Arzoomanian R, Dixon M, et al. A phase 1 study of AG3340, a matrix metalloproteinase (MMP) inhibitor in patients having advanced cancer [abstract]. Proc Nat Can Inst-Eur Org Res Treat Can 1998.
142. Wilding G, Small E, Ripple G, Keller M, Yuen G, Collier M. Phase 1 study of AG3340, a matrix metalloproteinase inhibitor in combination with mitoxantrone/prednisone in patients having advanced prostate cancer [abstract]. Proceedings of Nat Can Inst-Eur Org Res Treat Can 1998.
143. D'Olimpio J, Hande K, Collier M, Michelson G, Paradiso N, Clendeninn N. Phase I study of the matrix metalloproteinase inhibitor AG3340 in combination with paclitaxel and carboplatin for the treatment of patients with advanced solid tumors [abstract]. Proc Am Soc Clin Oncol 1998;18:160.
144. Rugo HS, Budman D, Vogel C, et al. Phase II study of the matrix metalloprotease inhibitor prinomastat in patients with progressive breast cancer [abstract]. Proc ASCO 2001;20:187.
145. Ahmann FR, Saad F, Mercier R, et al. Interim results of a phase III study of the matrix metalloprotease inhibitor prinomastat in patients having metastatic, hormone refractory prostate cancer (HRPC) [abstract]. Proc ASCO 2001;20:692.
146. Smylie M, Mercier R, Aboulafia D, et al. Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer (NSCLC) [abstract]. Proc ASCO 2001;20:1226.
147. Pfizer Discontinues Phase III Trials of Prinomastat in Advanced Cancers but Continues Multiple Phase II Trials [Press Release]. New York: Pfizer Inc.; August 4, 2000.
148. Ferrante K, Winograd B, Canetta R. Promising new developments in cancer chemotherapy. Cancer Chemother Pharmacol 1999;43(Suppl 1):S61-8.
149. Hurwitz H, Humphrey J, Williams K, et al. A phase I trial of BMS-275291: A novel, nonhydroxamate, sheddase-sparing matrix metalloproteinase inhibitor (MMPI) with no dose-limiting arthritis [abstract]. Proc ASCO 2001;20:387.
150. Daniels R, Gupta E, Kollia G, et al. Safety and pharmacokinctics of BMS-275291, a novel matrix metalloproteinase inhibitor in healthy subjects [abstract]. Proc ASCO 2001;20:395.
151. Gupta E, Huang M, Mao Y, et al. Pharmacokinetic (PK) Evaluation of BMS-275291, a matrix metalloproteinase (MMP) inhibitor, in cancer patients [abstract]. Proc ASCO 2001;20:301.
152. Wood J, Muller M, Schnell M, Cozens R, O'Reilly T, Cox D. CGS 27023A, a potent and orally active matrix metalloprotease inhibitor with antitumor activity [abstract]. Proc Am Assoc Can Res 1998;39:83.
153. Yoshida H, Kasaoka T, Watanabe T, Nishiyama H, Okada M, Toyoshima M, et al. Matrix metalloproteinase inhibitor (MMPI) CGS27023A inhibited extravasation of B16-F10 melanoma cells in the experimental metastatic model [abstract]. Proc Am Assoc Can Res 1999; 40:705.
154. Levitt NC, Eskens FA, O'Byme KJ, Propper DJ, Denis LJ, Owen SJ, et al. Phase 1 and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (formerly CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 2001;7(7):1912-22.
155. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998;12: 12-26.
156. Lokeshwar BL. MMP inhibition in prostate cancer. Ann N Y Acad Sci 1999;878:271-89.
157. Fife RS, Rougraff BT, Proctor C, Sledge GWJ. Inhibition of proliferation and induction of apoptosis by doxycycline in cultured human osteosarcoma cells. J Lab Clin Med 1997;130: 530-4.
158. Seftor RE, Seftor EA, De Larco JE, Kleiner DE, Leferson J, Stetler-Stevenson WG, et al. Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin Exp Metastasis 1998;16:217-25.
159. Greenwald RA, Golub LM, Ramamurthy NS, Chowdhury M, Moak SA, Sorsa T. In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: Relationship to bone and cartilage degradation. Bone 1998;22:33-8.
160. Ryan ME, Ramamurthy S, Golub LM. Matrix metalloproteinases and their inhibition in periodontal treatment. Curr Opin Periodontol 1996;3:85-96.
161. Golub LM, Ramamurthy NS, McNamara TF, Gomes BC, Wolff MS, Casino A, et al. Tetracyclines inhibit tissue collagenase activity: A new mechanism in the treatment of periodontal disease. J Periodont Res 1984;19:651-5.
162. Gilbertson-Beadling S, Powers EA, Stamp-Cole M, Scott PS, Wallace TL, Copeland J, et al. The tetracyclines analogs minocycline and doxycycline inhibit angiogenesis in vitro by a nonmetalloproteinase mechanism. Cancer Chemother Pharmacol 1995;36:418-24.
163. Smith GN, Mickler EA, Hasty KA, Brandt KD. Specificity of inhibition of matrix metalloproteinase activity by doxycycline. Arthritis Rheum 1999;42:1140-6.
164. Fife R, Sledge GWJ. Effects of doxycycline on in vitro growth, migration, and gelatinase activity of breast carcinoma cells. J Lab Clin Med 1995;125:407-11.
165. Fife R, Sledge GWJ, Roth B, Proctor C. Effects of doxycycline on human prostate cancer cells in vitro. Cancer Lett 1998;127:37-41.
166. Duivenvoorden WC, Hirte H, Singh G. Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells. Invasion Metastasis 1997;17:312-22.
167. Sledge GWJ, Qulali M, Bone EA, Fife R. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Can Inst 1995;87: 1546-50.
168. Gordon MS, Battiato LA, Jones D, Roth B, Harrison-Mann B, Fife R, et al. A phase I trial of doxycycline (Doxy) in patients with cancer [abstract]. Proc Am Soc Clin Oncol 1997;16.
169. Selzer MG, Zhu B, Block NL, Lokeshwar BL. CMT-3, a chemically modified tetracycline, inhibits bony metastases and delays the development of paraplegia in a rat model of prostate cancer. Ann N Y Acad Sci 1999;878:678-82.
170. Rowinsky E, Eckhardt S, Rizzo J, Hammond L, Campbell E, Felton S, et al. Protracted daily treatment with Col-3, and oral tetracycline analog, matrix metalloproteinase (MMP) inhibitor, is feasible: A phase I pharmacokinetic and biological study. Proc Am Soc Clin Oncol 2000; 19:180.
171. Rudek MA, Figg WD, Dyer V, et al. A phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol 2001;19(2): 584-92.
172. Rudek MA, Home M, Figg WD, Dahut W, Dyer V, Pluda JM, et al. Reversible sideroblastic anemia associated with the tetracycline analogue COL-3. Am J Hematol 2001;67(1):51-3.
173. Ghate JV, Turner ML, Rudek MA, Figg WD, Dahut W, Dyer V, et al. Drug-induced lupus associated with COL-3: Report of 3 cases. Arch Dermatol 2001;137(4):471-4.
174. Munoz-Mateu M, de'Grafenried L, Eckhardt SG, et al. Pharmacodynamic studies of Col-3, a novel matrix metalloproteinase inhibitor, in patients with advanced cancer [abstract]. Proc Am Soc Clin Oncol 2001;20:302.
175. Cancer Trials. National Cancer Institute. 2001. http://www.cancer.gov/clinical.htm.
176. Rowinsky EK, Eckhardt SG, Rizzo J, et al. A phase I and pharmacokinetic (PK) study of COL-3, an oral tetracycline analog and selective matrix metalloproteinase (MMP) inhibitor [abstract]. Clin Cancer Res 2000;6:292a.
177. Cianfrocca M, Cooley TP, Lee JY, et al. Angiogenesis inhibits COL-3 in the treatment of AIDS-related Kaposi's sarcoma: A phase I AIDS Malignancy Consortium study. J Clin Oncol 2002; 20(1):153-9.
178. Delmas PD. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastasis. N Engl J Med 1996;335:1785-91.
179. Hortobagyi GN. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastasis. N Engl J Med 1996;335:1785-91.
180. Rodan GA, Fleisch HA. Biphosphonates: Mechanism of action. J Clin Invest 1996;97:2692-6.
181. Stearns ME, Wang M. Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice. Clin Exp Metastasis 1998;16:693-702.
182. Stearns ME. Alendronate blocks TGF-betal stimulated collagen 1 degradation by human prostate PC-3 ML cells. Clin Exp Metastasis 1998;16:332-9.
183. Teronen O, Heikkila P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, et al. MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci 1999;878:453-65.
184. Skotnicki JS, Zask A, Nelson FC, Albright JD, Levin JI. Design and synthetic considerations of matrix metalloproteinase inhibitors. Ann N Y Acad Sci 1999;878:61-72.
185. Lozonschi L, Sunamura M, Kobari M, Egawa S, Ding L, Matsuno S. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res 1999;59:1252-8.
186. Maekawa R, Maki H, Yoshida H, Hojo K, Tanaka H, Wada T, et al. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. Cancer Res 1999;59:1231-5.
187. Igarashi N, Kubota T, Otani Y, Matsuzaki SW, Watanabe M, Teramoto T, et al. Preventive effect of matrix metalloproteinase inhibitor, R-94138, in combination with mitomycin C or cisplatin on peritoneal dissemination of human gastric cancer cell line TMK-1 in nude mice. Jpn J Cancer Res 1999;90:116-21.
188. Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, et al. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. J Med Chem 1998;41:640-9.
189. Kido A, Tsutsumi M, Iki K, Motoyama M, Takahama M, Tsujiuchi T, et al. Inhibition of spontaneous rat osteosarcoma lung metastasis by 3S-[4-(N-hydroxyamino)-2R-isobutylsuccinyl]amino-1-methoxy-3,4-dihydroc arbostyril, a novel matrix metalloproteinase inhibitor. Jpn J Cancer Res 1999;90:333-41.
190. Stockman BJ, Waldon DJ, Gates JA, Scahill TA, Kloosterman DA, Mizsak SA, et al. Solution structures of stromelysin complexed to thiadiazole inhibitors. Protein Sci 1998;7:2281-6.
191. Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkila P, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 1999;17:768-74.
192. Drummond AH, Beckett P, Brown PD, Bone EA, Davidson AH, Galloway WA, et al. Preclinical and clinical studies of MMP inhibitors in cancer. Ann N Y Acad Sci 1999;878:228-35.
193. Hooper NM, Karran EH, Turner AJ. Membrane protein secretases. Biochem J 1997;321: 265-79.
194. Lombard MA, Wallace TL, Kubicek MF, Petzold GL, Mitchell MA, Hendges SK, et al. Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-alpha receptors in a human colon adenocarcinoma (Colo 205) cell line. Cancer Res 1998;58:4001-7.
195. Williams LM, Gibbons DL, Gearing A, Maini RN, Feldmann M, Brennan FM. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures. J Clin Invest 1996;97:2833-41.
196. Dong J, Opresko LK, Dempsey PJ, Lauffenburger DA, Coffey RJ, Wiley HS. Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor. Proc Natl Acad Sci USA 1999;96:6235-40.